Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

 Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

Shots:

  • The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries, 209 patients received at least one dose of IMU-838 vs PBO and 197 patients completed @24-wks. treatment period
  • The study resulted in meeting its 1EPs & 2EPs: 62% & 70% reduction in CUA MRI lesions up to @24wks. in patients receiving IMU-838 (45mg & 30mg qd). Rate of treatment-emergent AEs (42.9% vs 43.5%); rate of treatment withdrawals (5.0% vs 7.2%)
  • Additionally, the company has reported financial results of Q2’20 with $48.6M in cash and cash equivalents. IMU-838 is an orally available DHOD inhibitor, acts on activated T and B cells and leave other immune cells largely unaffected, allowing the immune system to stay functioning

Click here to­ read full press release/ article | Ref: Immunic | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post